HLA class II haplotype and quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria

Blood

Volumn 100, Issue 1, 2002, Pages 22-28

  Shichishima, Tsutomu ^a,b,c,d   Okamoto, Masatoshi ^a,b,c,d   Ikeda, Kazuhiko ^a,b,c,d   Kaneshige, Toshihiko ^a,b,c,d   Sugiyama, Haruo ^a,b,c,d   Terasawa, Takashi ^a,b,c,d   Osumi, Kazuoki ^a,b,c,d   Maruyama, Yukio ^a,b,c,d  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d Otsuka Tokyo Assay Laboratories   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR ANTIGEN; RNA;

ADULT; AGED; ALLELE; APLASTIC ANEMIA; ARTICLE; BONE MARROW; CELL PROLIFERATION; CLONE; CONTROLLED STUDY; FEMALE; GENOTYPE; GRANULOCYTE; HAPLOTYPE; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; NEPHROBLASTOMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0036660403     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.1.22     Document Type: Article

References (67)

1. Rosse WF, Ware RE. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood. 1995;86:3277-3286.
2. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A. 1983;80:5066-5070.
3. Shichishima T, Terasawa T, Hashimoto C, Ohto H, Uchida T, Maruyama Y. Heterogeneous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes. Br J Haematol. 1991;78:545-550.
4. Young NS. The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated. Blood. 1992;79:1385-1392.
5. Kawagoe K, Kitamura D, Okabe M, et al. Glycosylphosphatidylinositol-anchor-deficient mice: implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria. Blood. 1996;87:3600-3606.
6. Brodsky RA, Vala MS, Barber JP, Medof ME, Jones RJ. Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A. 1997;94:8756-8760.
7. Takami A, Zang W, Wang H, Matsuda T, Nakao S. Cytotoxicity against lymphoblastoid cells mediated by a T-cell clone from an aplastic anaemia patient: role of CD59 on target cells. Br J Haematol. 1999;107:791-796.
8. Asea A, Kraeft S-K, Kurt-Jones EA, et al. HSP 70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med. 2000;6:435-442.
9. Karadimitris A, Manavalan JS, Thaler HT, et al. Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood. 2000;96:2613-2620.
10. Romagnoli P, Bron C. Defective TCR signaling events in glycosylphosphatidylinositol-deficient T cells derived from paroxysmal nocturnal hemoglobinuria patients. Int Immunol. 1999;11:1411-1422.
11. Young NS, Maciejewski JP. Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes "Why? Why? Why?" J Clin Invest. 2000;106:637-641.
12. Horikawa K, Nakakuma H, Kawaguchi T, et al. Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome. Blood. 1997;90:2716-2722.
13. Ware RE, Nishimura J, Moody MA, Smith C, Rosse WF, Howard TA. The PIG-A mutation and absence of glycosylphosphatidylinositol-linked proteins do not confer resistance to apoptosis in paroxysmal nocturnal hemoglobinuria. Blood. 1998;92:2541-2550.
14. Shichishima T, Saitoh Y, Terasawa T, Ogawa K, Maruyama Y. Relationship between the phenotypes of circulating erythrocytes and cultured erythroblasts in paroxysmal nocturnal hemoglobinuria. Blood. 1997;90:435-443.
15. - hematopoiesis is reconstituted following intercellular transfer of GPI-anchored proteins. Proc Natl Acad Sci U S A. 1996;93:7938-7943.
16. Lewis SM, Dacie JV. The aplastic anaemia-paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol. 1967;13:236-251.
17. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253-1258.
18. Socié G, Mary J-Y, de Gramont A, et al. Paroxysmal nocturnal hemoglobinuria: long-term follow-up and prognostic factors. Lancet. 1996;348:573-577.
19. Fujioka S, Asai T. Prognostic features of paroxysmal nocturnal hemoglobinuria in Japan. Nippon Ketsueki Gakkai Zasshi. 1989;52:1386-1394.
20. Tichelli A, Gratwohl A, Wursch A, Nissen C, Speck B. Late haematological complications in severe aplastic anaemia. Br J Haematol. 1988;69:413-418.
21. Young N, Griffith P, Brittain E, et al. A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood. 1988;72:1861-1869.
22. Ware RE, Hall SE, Rosse WF. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med. 1991;325:991-996.
23. Rugman FP, Ashby D, Davies JM, Does HLA-DR predict response to specific immunosuppressive therapy in aplastic anaemia? [letter]. Br J Haematol. 1990;74:545-546.
24. Nakao S, Yamaguchi M, Saito M, et al. HLA-DR2 predicts a favorable response to cyclosporin therapy in patients with bone marrow failure [letter]. Am J Hematol. 1992;40:239-240.
25. Chapuis B, von Fliedner M, Merica JH, et al. Increased frequency of DR2 in patients with aplastic anaemia and increased DR sharing in their parents. Br J Haematol. 1986;63:51-57.
26. Nimer SD, Ireland P, Meshkinpour A, Frane M. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood. 1994;84:923-927.
27. Shao W, Tian D, Liu C, Sun X, Zhang X. Aplastic anemia is associated with HLA-DRB1*1501 in northern Han Chinese. Int J Hematol. 2000;71:350-352.
28. Young NS, Alter BP. Aplastic Anemia Acquired and Inherited. Philadelphia, PA: WB Saunders; 1994.
29. Ustariz CR, Aree S, Hernández P, Almaguer M, Perez S, Ballester JM. HLA antigens in paroxysmal nocturnal hemoglobinuria. Acta Haematol. 1980;63:52-54.
30. Zeng W, Maciejewski JP, Chen G, Young NS. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest. 2001;108:765-773.
31. + T cells proliferating in response to influenza A antigen. J Clin Invest. 1999;104:63-67.
32. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990;60:509-520.
33. Patmasiriwat P, Faizer GC, Claxton D, Kantarjian H, Saunders GF. Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities. Leukemia. 1996;10:1127-1133.
34. Baird PN, Simmonds PJ. Expression of the Wilms' tumor gene (WT1) in normal hematopoiesis. Exp Hematol. 1997;25:312-320.
35. + hematopoietic progenitors during fetal development and early clonogenic growth [letter]. Blood. 1997;89:3486-3487.
36. Armstrong JF, Pritchard-Jones K, Bickmore WA, Hastie ND, Bard JB. The expression of the Wilms' tumor gene, WT1, in the developing mammalian embryo. Mech Dev. 1993;40:85-97.
37. Maheswaran S, Park S, Bernard A, et al. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A. 1993;90:5100-5104.
38. Johnstone RW, See RH, Sells SF, et al. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol. 1996;16:6945-6956.
39. Johnstone RW, Wang J, Tommerup N, Vissing H, Roberts T, Shi Y. Ciao 1 is a novel WD40 protein that interacts with the tumor suppressor protein WT1. J Biol Chem. 1998;273:10880-10887.
40. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of wild-type Wilms' tumor gene WT1 product. Immunogenetics. 2000;51:99-107.
41. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34 (+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198-2203.
42. Ohminami H, Yasukawa M, Fujita S, et al. HLA class I-restricted lysis of leukemia cells by a CD8 (+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286-293.
43. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000;96:1480-1489.
44. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071-3079.
45. Messen HD, Renkl HJ, Rodeck U, Kari C, Schwartz S, Thiel E. Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Int J Cancer. 1997;70:518-523.
46. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia. 1999;13:393-399.
47. Shichishima T, Terasawa T, Saitoh Y, Hashimoto C, Ohto H, Maruyama Y. Diagnosis of paroxysmal nocturnal haemoglobinuria by phenotypic analysis of erythrocytes using two-colour flow cytometry with monoclonal antibodies to DAF and CD59/MACIF. Br J Haematol. 1993;85:378-386.
48. Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood. 1996; 87:5332-5340.
49. Bennett JM, Catovsky D, Daniel M-T, et al. Proposal for the classification of the acute leukaemias. Br J Haematol. 1976;33:451-458.
50. Kitamura K, Urabe A. Aplastic anemia: immunosuppressive therapy in multi center trial in Japan. Nippon Ketsueki Gakkai Zasshi. 1989;52:1361-1369.
51. Noji H, Shichishima T, Saitoh Y, et al. The distribution of PIG-A gene abnormalities in paroxysmal nocturnal hemoglobinuria granulocytes and cultured erythroblasts. Exp Hematol. 2001;29:391-400.
52. Sugita Y, Mazda T, Tomita M. Amino-terminal amino acid sequence and chemical and functional properties of a membrane attack complexinhibitory factor from human erythrocyte membranes. J Biochem. 1989;106:589-592.
53. Sambrook J, Fritsch EF, Maniatis T. Analysis and cloning of eukaryotic genomic DNA. In: Nolan C, ed. Molecular Cloning, A Laboratory Manual. 2nd ed. Vol 2. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY: 1989:9.1-9.59.
54. Kaneshige T, Hashimoto M, Matsumoto Y, et al. Serologic and nucleotide sequencing analyses of a novel DR52-associated DRB1 allele with the DR 'NJ25' specificity, designated DRB1*1307. Hum Immunol. 1991;41:151-159.
55. Sengar DPS, Goldstein R. Comprehensive typing of DQB1 alleles by PCR-RFLP. Tissue Antigens. 1994;43:242-248.
56. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens. 1993;41:119-134.
57. Hashimoto M, Kinoshita T, Yamasaki M, et al. Gene frequencies and haplotype associations within the HLA region in 916 unrelated Japanese individuals. Tissue Antigens. 1994;44:166-173.
58. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class loci in the Japanese population. Tissue Antigens. 2000;56:522-529.
59. Held CA, Stevens J, Lival KJ, Williams PM. Realtime quantitative PCR. Genome Res. 1996;6:986-994.
60. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A. 1991;88:7276-7280.
61. Krauter J, Watties MP, Nagel S, et al. Real-time RT-PCR for the detection and quantitation of AML/MTG8 fusion transcripts in t(8; 21)-positive AML patients. Br J Haematol. 1999;107:80-85.
62. Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporindependent aplastic anemia. Blood. 1994;84:4257-4261.
63. Schrezenmeier H, Hertenstein B, Wagner B, Raghavachar A, Heimpel H. A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins. Exp Hematol. 1995;23:81-87.
64. Purow DB, Howard TA, Marcus SJ, Rosse WF, Ware RE. Genetic instability and the etiology of somatic PIG-A mutations in paroxysmal nocturnal hemoglobinuria. Blood Cells Mol Dis. 1999;15:81-91.
65. Hattori H, Machii T, Ueda E, Shibano M, Kageyama T. Increased frequency of somatic mutations at glycophorin A loci in patients with aplastic anaemia, myelodysplastic syndrome and paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1997;98:384-391.
66. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 2001;20:1897-1909.
67. Inoue K, Ogawa H, Yamagami T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood. 1996;88:2267-2278.